# Comparison of the Extent to Which the Drug Given as Two Different Capsule Sizes Becomes Available to the Body

> **NCT04845841** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 16 (actual)

## Conditions studied

- Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men

## Interventions

- **DRUG:** Elinzanetant (BAY3427080) treatment A
- **DRUG:** Elinzanetant (BAY3427080) treatment B

## Key facts

- **NCT ID:** NCT04845841
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-09
- **Primary completion:** 2021-06-01
- **Final completion:** 2021-06-01
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2023-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04845841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04845841, "Comparison of the Extent to Which the Drug Given as Two Different Capsule Sizes Becomes Available to the Body". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04845841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*